Hrt Financial LP Mersana Therapeutics, Inc. Transaction History

Hrt Financial LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.0 - $4.45 $519,378 - $1.16 Million	259,689 New	259,689 $521,000
Q4 2023 Feb 09, 2024	BUY	$1.11 - $2.34 $46,215 - $97,428	41,636 Added 64.87%	105,815 $245,000
Q3 2023 Nov 13, 2023	BUY	$1.06 - $3.91 $68,029 - $250,939	64,179 New	64,179 $81,000
Q4 2022 Feb 10, 2023	SELL	$5.65 - $7.86 $574,056 - $798,599	-101,603 Reduced 90.06%	11,210 $65,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $522,324 - $902,504	112,813 New	112,813 $762,000
Q2 2022 Aug 12, 2022	SELL	$2.84 - $5.0 $500,061 - $880,390	-176,078 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $221,243 - $392,204	59,156 Added 50.59%	176,078 $702,000
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $640,732 - $1.15 Million	116,922 New	116,922 $727,000
Q2 2021 Aug 16, 2021	SELL	$13.28 - $18.07 $423,618 - $576,414	-31,899 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$15.31 - $26.52 $488,373 - $845,961	31,899 New	31,899 $516,000

130

104M

58.5K

471K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $56.4M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.